New

Neurofibromatosis Type I Market

2021

Neurofibromatosis Type I Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Benign Eye Tumor, Brain Tumor, Adrenal Gland Tumor, Spinal Cord Tumor, and Malignant Peripheral Nerve Sheath Tumors); Technology (Diagnostics, Medication Or Drug Therapy, Surgery, Focused Radiation Therapy, Chemotherapy, Genetic Counseling, and Palliative Care); End Use (Hospitals, Clinics, and Others), and Geography

| Report Code: TIPRE00023216 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Neurofibromatosis Type I Market 2028 By Type, Technology, End Use, and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Neurofibromatosis happens due to a genetic mutation, resulting in tumor formation in various parts of a body, along with nerve tissues, brain, and spinal cord. Between the three types of this disease, neurofibromatosis type I (NF1) is the most general. Generally diagnosed in early adulthood or childhood, NF1 records to affect one behind each 2,000-2,500 people globally. Neurofibromatosis type I is distinguished by severe skin pigmentation, i.e., skin color changes and tumor formation. Though benign initially, these tumors may turn malignant in later stages, making it critical to seek the appropriate treatment in the early stages.Symptoms of neurofibromatosis type I typically include multiple flat patches or café-au-lait spots, which enlarge and multiply as patients grow older.

MARKET SCOPE

The "Global Neurofibromatosis Type I Market Analysis to 2028" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Neurofibromatosis Type I market with detailed market segmentation by type, technology, end use, and geography. The report provides key statistics on the market status of the leading Neurofibromatosis Type I market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on type, the global Neurofibromatosis Type I market is segmented into benign eye tumor, brain tumor, adrenal gland tumor, spinal cord tumor, and malignant peripheral nerve sheath tumors.
  •  On the basis of technology, the market is segmented into diagnostics, medication or drug therapy, surgery, focused radiation therapy, chemotherapy, genetic counseling, and palliative care
  •  On the basis of end use, the market is segmented into hospitals, clinics, and others.

MARKET DYNAMICS
Drivers

  •   Growing importance of aesthetic appeal.
  •   Increase in research and development initiatives.
  •   Rising focus on drugs that affect the ras signaling pathway inside the tumor cell

Restraints

  •   The difficulty in conduction clinical trials for pediatric population is the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Neurofibromatosis Type I market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Neurofibromatosis Type I market in these regions.

IMPACT OF COVID-19 ON NEUROFIBROMATOSIS TYPE I MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Neurofibromatosis Type I market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Neurofibromatosis Type I market are anticipated to lucrative growth opportunities in the future with the rising demand for Neurofibromatosis Type I in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Neurofibromatosis Type I market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  GL Pharm Tech Corporation
  •  Erasmus Medical Center
  •  Assistance Publique - Hopitaux de Paris
  •  Texas Neurofibromatosis Foundation
  •  University of Alabama at Birmingham
  •  Indiana University
  •  Merck
  •  AstraZeneca
  •  SpringWorks Therapeutics
  •  NFlection Therapeutics

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neurofibromatosis Type I Market - By Type
1.3.2 Neurofibromatosis Type I Market - By Technology
1.3.3 Neurofibromatosis Type I Market - By End Use
1.3.4 Neurofibromatosis Type I Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NEUROFIBROMATOSIS TYPE I MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEUROFIBROMATOSIS TYPE I MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROFIBROMATOSIS TYPE I MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROFIBROMATOSIS TYPE I - GLOBAL MARKET OVERVIEW
6.2. NEUROFIBROMATOSIS TYPE I - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. NEUROFIBROMATOSIS TYPE I MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. BENIGN EYE TUMOR
7.3.1. Overview
7.3.2. Benign Eye Tumor Market Forecast and Analysis
7.4. BRAIN TUMOR
7.4.1. Overview
7.4.2. Brain Tumor Market Forecast and Analysis
7.5. ADRENAL GLAND TUMOR
7.5.1. Overview
7.5.2. Adrenal Gland Tumor Market Forecast and Analysis
7.6. SPINAL CORD TUMOR
7.6.1. Overview
7.6.2. Spinal Cord Tumor Market Forecast and Analysis
7.7. MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
7.7.1. Overview
7.7.2. Malignant Peripheral Nerve Sheath Tumors Market Forecast and Analysis
8. NEUROFIBROMATOSIS TYPE I MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. DIAGNOSTICS
8.3.1. Overview
8.3.2. Diagnostics Market Forecast and Analysis
8.4. MEDICATION OR DRUG THERAPY
8.4.1. Overview
8.4.2. Medication Or Drug Therapy Market Forecast and Analysis
8.5. SURGERY
8.5.1. Overview
8.5.2. Surgery Market Forecast and Analysis
8.6. FOCUSED RADIATION THERAPY
8.6.1. Overview
8.6.2. Focused Radiation Therapy Market Forecast and Analysis
8.7. CHEMOTHERAPY
8.7.1. Overview
8.7.2. Chemotherapy Market Forecast and Analysis
8.8. GENETIC COUNSELING
8.8.1. Overview
8.8.2. Genetic Counseling Market Forecast and Analysis
8.9. PALLIATIVE CARE
8.9.1. Overview
8.9.2. Palliative Care Market Forecast and Analysis
9. NEUROFIBROMATOSIS TYPE I MARKET - REVENUE AND FORECASTS TO 2028 - END USE
9.1. OVERVIEW
9.2. END USE MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. CLINICS
9.4.1. Overview
9.4.2. Clinics Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. NEUROFIBROMATOSIS TYPE I MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neurofibromatosis Type I Market Overview
10.1.2 North America Neurofibromatosis Type I Market Forecasts and Analysis
10.1.3 North America Neurofibromatosis Type I Market Forecasts and Analysis - By Type
10.1.4 North America Neurofibromatosis Type I Market Forecasts and Analysis - By Technology
10.1.5 North America Neurofibromatosis Type I Market Forecasts and Analysis - By End Use
10.1.6 North America Neurofibromatosis Type I Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neurofibromatosis Type I Market
10.1.6.1.1 United States Neurofibromatosis Type I Market by Type
10.1.6.1.2 United States Neurofibromatosis Type I Market by Technology
10.1.6.1.3 United States Neurofibromatosis Type I Market by End Use
10.1.6.2 Canada Neurofibromatosis Type I Market
10.1.6.2.1 Canada Neurofibromatosis Type I Market by Type
10.1.6.2.2 Canada Neurofibromatosis Type I Market by Technology
10.1.6.2.3 Canada Neurofibromatosis Type I Market by End Use
10.1.6.3 Mexico Neurofibromatosis Type I Market
10.1.6.3.1 Mexico Neurofibromatosis Type I Market by Type
10.1.6.3.2 Mexico Neurofibromatosis Type I Market by Technology
10.1.6.3.3 Mexico Neurofibromatosis Type I Market by End Use
10.2. EUROPE
10.2.1 Europe Neurofibromatosis Type I Market Overview
10.2.2 Europe Neurofibromatosis Type I Market Forecasts and Analysis
10.2.3 Europe Neurofibromatosis Type I Market Forecasts and Analysis - By Type
10.2.4 Europe Neurofibromatosis Type I Market Forecasts and Analysis - By Technology
10.2.5 Europe Neurofibromatosis Type I Market Forecasts and Analysis - By End Use
10.2.6 Europe Neurofibromatosis Type I Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neurofibromatosis Type I Market
10.2.6.1.1 Germany Neurofibromatosis Type I Market by Type
10.2.6.1.2 Germany Neurofibromatosis Type I Market by Technology
10.2.6.1.3 Germany Neurofibromatosis Type I Market by End Use
10.2.6.2 France Neurofibromatosis Type I Market
10.2.6.2.1 France Neurofibromatosis Type I Market by Type
10.2.6.2.2 France Neurofibromatosis Type I Market by Technology
10.2.6.2.3 France Neurofibromatosis Type I Market by End Use
10.2.6.3 Italy Neurofibromatosis Type I Market
10.2.6.3.1 Italy Neurofibromatosis Type I Market by Type
10.2.6.3.2 Italy Neurofibromatosis Type I Market by Technology
10.2.6.3.3 Italy Neurofibromatosis Type I Market by End Use
10.2.6.4 Spain Neurofibromatosis Type I Market
10.2.6.4.1 Spain Neurofibromatosis Type I Market by Type
10.2.6.4.2 Spain Neurofibromatosis Type I Market by Technology
10.2.6.4.3 Spain Neurofibromatosis Type I Market by End Use
10.2.6.5 United Kingdom Neurofibromatosis Type I Market
10.2.6.5.1 United Kingdom Neurofibromatosis Type I Market by Type
10.2.6.5.2 United Kingdom Neurofibromatosis Type I Market by Technology
10.2.6.5.3 United Kingdom Neurofibromatosis Type I Market by End Use
10.2.6.6 Rest of Europe Neurofibromatosis Type I Market
10.2.6.6.1 Rest of Europe Neurofibromatosis Type I Market by Type
10.2.6.6.2 Rest of Europe Neurofibromatosis Type I Market by Technology
10.2.6.6.3 Rest of Europe Neurofibromatosis Type I Market by End Use
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neurofibromatosis Type I Market Overview
10.3.2 Asia-Pacific Neurofibromatosis Type I Market Forecasts and Analysis
10.3.3 Asia-Pacific Neurofibromatosis Type I Market Forecasts and Analysis - By Type
10.3.4 Asia-Pacific Neurofibromatosis Type I Market Forecasts and Analysis - By Technology
10.3.5 Asia-Pacific Neurofibromatosis Type I Market Forecasts and Analysis - By End Use
10.3.6 Asia-Pacific Neurofibromatosis Type I Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neurofibromatosis Type I Market
10.3.6.1.1 Australia Neurofibromatosis Type I Market by Type
10.3.6.1.2 Australia Neurofibromatosis Type I Market by Technology
10.3.6.1.3 Australia Neurofibromatosis Type I Market by End Use
10.3.6.2 China Neurofibromatosis Type I Market
10.3.6.2.1 China Neurofibromatosis Type I Market by Type
10.3.6.2.2 China Neurofibromatosis Type I Market by Technology
10.3.6.2.3 China Neurofibromatosis Type I Market by End Use
10.3.6.3 India Neurofibromatosis Type I Market
10.3.6.3.1 India Neurofibromatosis Type I Market by Type
10.3.6.3.2 India Neurofibromatosis Type I Market by Technology
10.3.6.3.3 India Neurofibromatosis Type I Market by End Use
10.3.6.4 Japan Neurofibromatosis Type I Market
10.3.6.4.1 Japan Neurofibromatosis Type I Market by Type
10.3.6.4.2 Japan Neurofibromatosis Type I Market by Technology
10.3.6.4.3 Japan Neurofibromatosis Type I Market by End Use
10.3.6.5 South Korea Neurofibromatosis Type I Market
10.3.6.5.1 South Korea Neurofibromatosis Type I Market by Type
10.3.6.5.2 South Korea Neurofibromatosis Type I Market by Technology
10.3.6.5.3 South Korea Neurofibromatosis Type I Market by End Use
10.3.6.6 Rest of Asia-Pacific Neurofibromatosis Type I Market
10.3.6.6.1 Rest of Asia-Pacific Neurofibromatosis Type I Market by Type
10.3.6.6.2 Rest of Asia-Pacific Neurofibromatosis Type I Market by Technology
10.3.6.6.3 Rest of Asia-Pacific Neurofibromatosis Type I Market by End Use
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neurofibromatosis Type I Market Overview
10.4.2 Middle East and Africa Neurofibromatosis Type I Market Forecasts and Analysis
10.4.3 Middle East and Africa Neurofibromatosis Type I Market Forecasts and Analysis - By Type
10.4.4 Middle East and Africa Neurofibromatosis Type I Market Forecasts and Analysis - By Technology
10.4.5 Middle East and Africa Neurofibromatosis Type I Market Forecasts and Analysis - By End Use
10.4.6 Middle East and Africa Neurofibromatosis Type I Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neurofibromatosis Type I Market
10.4.6.1.1 South Africa Neurofibromatosis Type I Market by Type
10.4.6.1.2 South Africa Neurofibromatosis Type I Market by Technology
10.4.6.1.3 South Africa Neurofibromatosis Type I Market by End Use
10.4.6.2 Saudi Arabia Neurofibromatosis Type I Market
10.4.6.2.1 Saudi Arabia Neurofibromatosis Type I Market by Type
10.4.6.2.2 Saudi Arabia Neurofibromatosis Type I Market by Technology
10.4.6.2.3 Saudi Arabia Neurofibromatosis Type I Market by End Use
10.4.6.3 U.A.E Neurofibromatosis Type I Market
10.4.6.3.1 U.A.E Neurofibromatosis Type I Market by Type
10.4.6.3.2 U.A.E Neurofibromatosis Type I Market by Technology
10.4.6.3.3 U.A.E Neurofibromatosis Type I Market by End Use
10.4.6.4 Rest of Middle East and Africa Neurofibromatosis Type I Market
10.4.6.4.1 Rest of Middle East and Africa Neurofibromatosis Type I Market by Type
10.4.6.4.2 Rest of Middle East and Africa Neurofibromatosis Type I Market by Technology
10.4.6.4.3 Rest of Middle East and Africa Neurofibromatosis Type I Market by End Use
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neurofibromatosis Type I Market Overview
10.5.2 South and Central America Neurofibromatosis Type I Market Forecasts and Analysis
10.5.3 South and Central America Neurofibromatosis Type I Market Forecasts and Analysis - By Type
10.5.4 South and Central America Neurofibromatosis Type I Market Forecasts and Analysis - By Technology
10.5.5 South and Central America Neurofibromatosis Type I Market Forecasts and Analysis - By End Use
10.5.6 South and Central America Neurofibromatosis Type I Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neurofibromatosis Type I Market
10.5.6.1.1 Brazil Neurofibromatosis Type I Market by Type
10.5.6.1.2 Brazil Neurofibromatosis Type I Market by Technology
10.5.6.1.3 Brazil Neurofibromatosis Type I Market by End Use
10.5.6.2 Argentina Neurofibromatosis Type I Market
10.5.6.2.1 Argentina Neurofibromatosis Type I Market by Type
10.5.6.2.2 Argentina Neurofibromatosis Type I Market by Technology
10.5.6.2.3 Argentina Neurofibromatosis Type I Market by End Use
10.5.6.3 Rest of South and Central America Neurofibromatosis Type I Market
10.5.6.3.1 Rest of South and Central America Neurofibromatosis Type I Market by Type
10.5.6.3.2 Rest of South and Central America Neurofibromatosis Type I Market by Technology
10.5.6.3.3 Rest of South and Central America Neurofibromatosis Type I Market by End Use
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL NEUROFIBROMATOSIS TYPE I MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. NEUROFIBROMATOSIS TYPE I MARKET, KEY COMPANY PROFILES
13.1. GL PHARM TECH CORPORATION
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ERASMUS MEDICAL CENTER
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. TEXAS NEUROFIBROMATOSIS FOUNDATION
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. UNIVERSITY OF ALABAMA AT BIRMINGHAM
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. INDIANA UNIVERSITY
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MERCK
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. ASTRAZENECA
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. SPRINGWORKS THERAPEUTICS
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. NFLECTION THERAPEUTICS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS

The List of Companies

1. GL Pharm Tech Corporation
2. Erasmus Medical Center
3. Assistance Publique - Hopitaux de Paris
4. Texas Neurofibromatosis Foundation
5. University of Alabama at Birmingham
6. Indiana University
7. Merck
8. AstraZeneca
9. SpringWorks Therapeutics
10. NFlection Therapeutics
11. CereXis
12. Nobelpharma
13. INTiDYN
14. Genentech
15. Array BioPharma
TIPRE00023216
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.